津力达颗粒治疗多囊卵巢综合征的疗效观察

发布时间：2018-03-14 17:27

本文选题：多囊卵巢综合征　切入点：津力达颗粒　出处：《云南中医学院》2015年硕士论文　论文类型：学位论文

【摘要】：目的:评估津力达颗粒在改善多囊卵巢综合征患者临床症状、胰岛素抵抗、性激素水平方面的疗效。方法:2013年12月-2014年3月在云南省第一人民医院的门诊、住院的多囊卵巢综合症患者,共入组68例,按入组标准随机的分为津力达组即治疗组(n=37)和对照组(n=31),分别予以津力达颗粒联合二甲双胍及达英-35治疗对比单纯使用二甲双胍及达英-35治疗。连续治疗3个周期,连续21天为1个周期,每个周期结束后,停药7天后开始下一个周期的治疗。观察和统计两组治疗前后及两组间临床症状、体重指数(BMI)、HOMA胰岛素抵抗指数(HOMA-IRI)、性激素:促卵泡生成素(FSH)、促黄体生成素(LH)、泌乳素(PRL)、雌二醇(E2)、雄激素总睾酮(T)的变化。结果:1.两组间比较治疗前两组症状评分无差异,对照组治疗前后症候改善不明显(PO.O5),治疗组治疗前后症候改善明显(P0.01);治疗后津力达组症候改善情况显著优于对照组(P0.05)。2.两组都可显著降低患者BMI水平(两组均p0.01)。比较两组患者BMI下降的程度(p0.01)有显著差异,津力达组优于对照组。3.两组都可显著降低患者HOMA-IR指数(p0.01)。比较两组患者HOMA-IR指数的变化程度(p0.05)有统计学差异,津力达组优于对照组。4.两组月经恢复都达到80%以上。对照组、津力达组治疗后都显著降低了患者的LH/FSH比值、T、PRL,p值均为p0.01。两组LH/FSH比值、PRL都达到了正常但两组间比较没有统计学意义(P0.05);组间比较两组间T下降水平有显著性差异(p0.01),津力达组优于对照组。结论:津力达颗粒联合二甲双胍及达英-35治疗多囊卵巢综合征可以明显改善症状,在减轻体重、改善胰岛素抵抗、降低T方面有显著疗效,疗效优于单用“二甲双胍+达英-35”方案,且无低血糖发生。
[Abstract]:Objective: to evaluate the efficacy of Jinlida granule in improving clinical symptoms, insulin resistance and sex hormone levels in patients with polycystic ovary syndrome (PCOS). A total of 68 patients with polycystic ovary syndrome (PCOS) were admitted to the hospital. According to the standard of entry, they were randomly divided into two groups: Jinlida group (treatment group) and control group (control group). They were treated with Jinlida granule combined with metformin and dain-35, respectively, and treated with metformin and dain-35 for 3 consecutive cycles. After the end of each cycle, the treatment of the next cycle began 7 days after the end of each cycle. The clinical symptoms of the two groups before and after treatment and between the two groups were observed and counted. Body mass index (BMI), HOMA insulin resistance index (HOMA-IRII), sex hormone: follicle stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL), estradiol (E _ 2), androgen total testosterone (T). Results there was no difference in symptom scores between the two groups before treatment. The symptoms of the control group were not significantly improved before and after treatment, but the symptoms of the treatment group were significantly improved before and after treatment (P 0.01), and the improvement of symptoms in the Jinlida group after treatment was significantly better than that in the control group (P 0.05). 2. Both groups could significantly reduce the level of BMI in both groups (P 0.01). There was a significant difference between the two groups in the degree of BMI decrease (P 0.01). Jinlida group is superior to control group .3.The two groups can significantly reduce the HOMA-IR index of patients with p0.01.Compared with the changes of HOMA-IR index in the two groups (p0.05), Zinlida group is better than control group .4.The menstrual recovery of both groups is more than 80%. After treatment, the LH/FSH ratio of the two groups was significantly decreased (P < 0.01). The LH/FSH ratio of the two groups was normal, but there was no significant difference between the two groups (P 0.05), and there was a significant difference in the level of T between the two groups (P 0.01), and there was no significant difference between the two groups in the level of T reduction (P < 0.05), and there was a significant difference between the two groups (P < 0.05), and there was a significant difference between the two groups (P < 0.05). Conclusion: the combination of Zinlida granules and metformin and Daf-35 can significantly improve the symptoms of polycystic ovary syndrome. It has significant curative effect in reducing weight, improving insulin resistance and reducing T. The curative effect is better than that of "metformin 35" alone, and there is no hypoglycemia.
【学位授予单位】：云南中医学院
【学位级别】：硕士
【学位授予年份】：2015
【分类号】：R711.75

【相似文献】